1 / 22

Quantification in emission tomography: challenges, solutions, performance and impact Irène Buvat

EuroMedIm 2006. Quantification in emission tomography: challenges, solutions, performance and impact Irène Buvat U678 INSERM, Paris buvat@imed.jussieu.fr http://www.guillemet.org/irene. What is quantification in emission tomography?. SPECT image. C kBq/ml.

gianna
Download Presentation

Quantification in emission tomography: challenges, solutions, performance and impact Irène Buvat

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. EuroMedIm 2006 Quantification in emission tomography: challenges, solutions, performance and impact Irène Buvat U678 INSERM, Paris buvat@imed.jussieu.fr http://www.guillemet.org/irene

  2. What is quantification in emission tomography? SPECT image C kBq/ml Density of dopaminergic transporters Extracting physiologically meaningfulvalues from PET or SPECT images

  3. Why do we need quantification? Cumulative survival of patients with T1–T4 laryngeal carcinomas (n = 34) CT C11-TYR PET PSR < 2 (5y survival, 67%) Cumulative survival (%) PSR ≥ 2 (5y survival, 34%) Supraglottic squamous cell carcinoma Time (mo) PSR: protein synthesis rate from C11-TYR PET de Boer et al, J Nucl Med 2004 Physiological parameters are richer than visual assessment • Differential diagnosis • Prognosis • Therapeutic management • Treatment monitoring • Radiotherapy

  4. Is quantification easy? N N ≠ k C ET image Radiotracer concentration C kBq/ml C kBq/ml C ≠ k’ f Radiotracer concentration Density of dopaminergic transporters No Find C=f(N) Find f = g(Ci, Pn)

  5. Deriving radiotracer concentration from ET images • patient motion • photon attenuation • photon scatter • limited spatial resolution • [randoms (PET)] • [deadtime] • tomographic reconstruction • measurement procedure What should be accounted for

  6. Patient and organ motions Lung FDG PET with respiratory motion without no gating Increase of lesion size from 10% to 30% Decrease of SUVmax from 5% to > 100% keeping one gate gating + combining gates Nehmeh et al, J Nucl Med 2002:876-881 Li et al, Med Phys 2006:1288-1298 Spurious or physiological (cardiac, respiratory) • Reduce scan duration • Gating (cardiac, respiratory, or both) and further processing Hot topic !

  7. Photon attenuation 1. Measure tissue density (e.g., using a CT) Tc99m cardiac SPECT no attenuation 230 p = R f 241 m attenuated 27 14 Attenuation introduces activity underestimation > 70% in SPECT and PET! 2. Pre or post correction, or model attenuation in reconstruction Very efficient Fine tuning stage (motion, contrast medium, aso)

  8. Photon scatter Tc99m cardiac SPECT • Subtraction of scattered photons after modelling scatter distribution p = R f 20% projection s unscattered scattered (37%) 20 to 50% of detected photons can be scattered (hence mislocated) in ET Decrease contrast • Better : towards relocation of scattered events Relocation under investigation (much less non zero elements in Rs, out of the FOV activity)

  9. Limited and non stationary spatial resolution • Multiply measured values by a recovery coefficient In SPECT inverse of the RC RC-1 FWHM 1 0.5 d spatial resolution 12 mm infinite contrast point source 0 detector position 2 6 10 14 18 Structure diameter (mm) • Invert a cross-contamination matrix Partial volume effect in ET max=100  = max<100 severely affects structures < 3 FWHM in size Introduces non stationary partial volume effect Definitely useful But all methods assume that functional contours same as anatomical contours

  10. Tomographic reconstruction • Control spatial resolution, so that partial volume effect can be predicted FBP, MLEM, OSEM, conjugate gradient ? Does that change quantitative accuracy? Boellaard et al, J Nucl Med 2001:808-817 Indirectly affects quantitation • Control noise level, which affects measurement variability Need for more systematic report on the spatial resolution / noise trade-off achieved by the reconstruction to determine quantitative accuracy

  11. Measurement procedure • Empirical work so far • Home-made approaches In PET, therapeutic follow-up based on TNR TNRmoy TNRmax TNR50 TNR75 sensitivity Feuardent et al, SNM 2005 1 - specificity Significant impact of VOI drawing Large room for improvement Need for optimization and standardization Hot topic : Definition of functional regions

  12. How accurate can one be in SPECT? restored activity (%) 120 100 80 60 40 20 0 putamen background Brain SPECT of dopaminergic system (no motion) binding potential = (Ap-Abgd)/Ap 10 8 6 4 2 0 Ap true no correction attenuation attenuation+scatter attenuation+ DD spatial resolution attenuation+scatter+DDSR attenuation+scatter+DDSR + partial volume Abgd Soret et al, J Nucl Med2003:1184-1193

  13. Need for accurate quantification in SPECT Differential diagnosis in presymptomatic patients BP 1 2 3 Without correction Alzheimer BP 4 6 With PVE correction Soret et al, Eur J Nucl Med Mol Imaging 2006 Lewy body dementia Brain SPECT of dopaminergic system Binding potentia (BP) estimate -58% +15% +12% -64% W/o PVE correction With PVE correction

  14. Example: quantification in FDG-PET Lung spheres diameter (in mm) 10.5 16 22 33 Different conditions 18 min acquisition 0.4 1.5 2.4 3.7 0.7 2 2.8 3.7 CT att correction 5.2 5.4 5.4 5.5 PVE correction 0.6 2.3 4.1 6.3 Max in tumor region True tumor/bgd ratio = 8 Clinical conditions (CPET!) Lung spheres diameter (in mm) - 6 min acquisition - Cs137 transmission scan for attenuation correction - No PVE correction - mean count value in the tumor region 10.5 16 22 33 0.5 1.4 2.4 3.5 Tumor/bgd ratio Feuardent et al, IEEE Trans Nucl Sci 2006

  15. 2nd step: deriving physiological parameters C kBq/ml Radiotracer concentration Density of dopaminergic transporters

  16. General and appropriate approach Dynamic image sequence Biochemical knowledge Blood sampling Tracer kinetic in regions of interest Model Arterial input function Fitting measurements to model Region-dependent physiological parameters e.g., glucose metabolic rate, blood flow, blood volume, mean transit time

  17. Practical trade-off Example of FDG-PET Glucose metabolic rate Full compartmental modeling Patlak SKA Physiological meaning SUV complexity • Simplifying the whole procedure to achieve some reasonable trade-off between feasibility and index usefulness

  18. Example of F18-FDG PET t = Ki AIF(q)dq 0 FDG made available to tumor Glucose metabolic rate Tumor (t) – unmetabolized FDG Ki = t AIF(q)dq 0 + unmetabolized FDG (t) Tumor FDG (t) SUV = ~ injected dose / dilution volume ~ injected dose / patient weight

  19. Accuracy depends on complexity • SUV versus Ki FDG-PET in accute lung injury Chen et al, J Nucl Med 2004:1583-1590 Quantitative accuracy depends on the relevance of the model used for physiological parameter estimates

  20. Conclusions • Quantification is feasible in PET and SPECT • Quantification is a complicated process, requiring tissue density map, perfectly controlled acquisition and processing protocols, high resolution anatomical information, accurate kinetic modeling • Accurate quantification is easier in PET than in SPECT, just because attenuation correction is more accessible, and mostly because spatial resolution is better • SPECT/CT and PET/CT scan could make quantification a clinical reality • Partial volume effect and motion are currently the toughest effects to deal with

  21. Conclusions • Quantification accuracy highly depends on the acquisition and processing protocols, and should be characterized • Meta-analyses are often impossible - or meaningless - given the variety and lack of information regarding acquisition and processing • Comparing quantitative values (e.g. for therapeutic follow-up, malignancy indices) requires highly controlled protocols to ensure constant acquisition and processing conditions

  22. Thank you for your attention Slides available on http://www.guillemet.org/irene

More Related